Lumos Pharma is focused on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. Lumos Pharma is led by an experienced management team with longstanding experience in the rare disease space. Lumos Pharma's lead compound is supported by the National Institutes of Health's Therapeutics for Rare and Neglected Diseases (TRND) program.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/06/16 | $34,000,000 | Series B |
Clarus Ventures Deerfield Management Company, L.P. Roche Venture Fund Sante Ventures UCB | undisclosed |
